Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1996 Feb;80(2):140–143. doi: 10.1136/bjo.80.2.140

Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

H B Hoh 1, C Hurley 1, C Claoue 1, M Viswalingham 1, D L Easty 1, P Goldschmidt 1, L M Collum 1
PMCID: PMC505405  PMID: 8814744

Abstract

AIMS: This study was designed to assess the relative efficacy of topical ganciclovir 0.15% gel and acyclovir 3% ointment in the treatment of herpes simplex dendritic keratitis. METHODS: Both treatment modalities were administered on a five times daily basis to patients suffering from herpes simplex keratitis. Patients were assigned randomly to one of the two treatment groups for the purpose of the trial. They were then examined on days 2, 7, 10, and 14 to assess the rate of healing of the dendritic ulceration. RESULTS: There was no statistically significant difference detected in the rate of healing between the two treatment groups over the course of the trial. CONCLUSIONS: Review of the relative efficacy of topical ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis showed that both treatment modalities were equally effective in their ability to heal the viral induced corneal ulceration. There were no significant side effects or adverse effects reported for either treatment modality.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birch C. J., Tyssen D. P., Tachedjian G., Doherty R., Hayes K., Mijch A., Lucas C. R. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis. 1992 Jul;166(1):108–112. doi: 10.1093/infdis/166.1.108. [DOI] [PubMed] [Google Scholar]
  2. Colin J., Tournoux A., Chastel C., Renard G. Kératite herpétique superficielle. Traitement comparatif en double insu par acycloriv et idoxuridine. Nouv Presse Med. 1981 Oct 10;10(36):2969-70, 2975. [PubMed] [Google Scholar]
  3. Collum L. M., Benedict-Smith A., Hillary I. B. Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration. Br J Ophthalmol. 1980 Oct;64(10):766–769. doi: 10.1136/bjo.64.10.766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collum L. M., Logan P., McAuliffe-Curtin D., Hung S. O., Patterson A., Rees P. J. Randomised double-blind trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex amoeboid corneal ulceration. Br J Ophthalmol. 1985 Nov;69(11):847–850. doi: 10.1136/bjo.69.11.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collum L. M., Power W. J., Collum A. The current management of herpetic eye disease. Doc Ophthalmol. 1992;80(2):201–205. doi: 10.1007/BF00161246. [DOI] [PubMed] [Google Scholar]
  6. Coster D. J., Jones B. R., Falcon M. G. Role of debridement in the treatment of herpetic keratitis. Trans Ophthalmol Soc U K. 1977 Jul;97(2):314–317. [PubMed] [Google Scholar]
  7. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  8. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Falcon M. G., Jones B. R. Antivirals for the therapy of herpetic eye disease. Trans Ophthalmol Soc U K. 1977 Jul;97(2):330–332. [PubMed] [Google Scholar]
  10. Furman P. A., St Clair M. H., Fyfe J. A., Rideout J. L., Keller P. M., Elion G. B. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol. 1979 Oct;32(1):72–77. doi: 10.1128/jvi.32.1.72-77.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Furman P. A., St Clair M. H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem. 1984 Aug 10;259(15):9575–9579. [PubMed] [Google Scholar]
  12. Ishida Y., Yokota Y., Tauchi H., Fukuda M., Takaoka T., Hayashi M., Matsuda H. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet. 1993 Feb 27;341(8844):560–561. doi: 10.1016/0140-6736(93)90323-9. [DOI] [PubMed] [Google Scholar]
  13. Kaufman H. E. Update on antiviral agents. Ophthalmology. 1985 Apr;92(4):533–536. doi: 10.1016/s0161-6420(85)34011-3. [DOI] [PubMed] [Google Scholar]
  14. Kläger A. J., Büchi E. R., Osusky R., Burek-Kozlowska A., Morell A. Topical immunoglobulins for epithelial herpes simplex keratitis. Ophthalmologica. 1993;207(2):78–81. doi: 10.1159/000310409. [DOI] [PubMed] [Google Scholar]
  15. Laibson P. R., Arentsen J. J., Mazzanti W. D., Eiferman R. A. Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic keratitis. Trans Am Ophthalmol Soc. 1977;75:316–324. [PMC free article] [PubMed] [Google Scholar]
  16. Lass J. H., Thoft R. A., Dohlman C. H. Idoxuridine-induced conjunctival cicatrization. Arch Ophthalmol. 1983 May;101(5):747–750. doi: 10.1001/archopht.1983.01040010747009. [DOI] [PubMed] [Google Scholar]
  17. Markham A., Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994 Sep;48(3):455–484. doi: 10.2165/00003495-199448030-00009. [DOI] [PubMed] [Google Scholar]
  18. Matthews T., Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S490–S494. doi: 10.1093/clinids/10.supplement_3.s490. [DOI] [PubMed] [Google Scholar]
  19. McGill J., Tormey P., Walker C. B. Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers. Br J Ophthalmol. 1981 Sep;65(9):610–613. doi: 10.1136/bjo.65.9.610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Oettle H., Wilborn F., Schmidt C. A., Siegert W. Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation. Blood. 1993 Oct 1;82(7):2257–2258. [PubMed] [Google Scholar]
  21. Poscher M. E. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS. 1994 Aug;8(8):1115–1117. [PubMed] [Google Scholar]
  22. Power W. J., Benedict-Smith A., Hillery M., Brady K., Collum L. M. Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study. Curr Eye Res. 1991;10 (Suppl):183–187. doi: 10.3109/02713689109020377. [DOI] [PubMed] [Google Scholar]
  23. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shiota H., Naito T., Mimura Y. Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. Curr Eye Res. 1987 Jan;6(1):241–245. doi: 10.3109/02713688709020098. [DOI] [PubMed] [Google Scholar]
  25. Smee D. F., Campbell N. L., Matthews T. R. Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides. Antiviral Res. 1985 Oct;5(5):259–267. doi: 10.1016/0166-3542(85)90040-3. [DOI] [PubMed] [Google Scholar]
  26. Smith K. O., Hodges S. L., Kennell W. L., Galloway K. S., Poirier R. H., Ogilvie K. K., Cheriyan U. O. Experimental ocular herpetic infections in rabbits. Treatment with 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine. Arch Ophthalmol. 1984 May;102(5):778–781. doi: 10.1001/archopht.1984.01040030626036. [DOI] [PubMed] [Google Scholar]
  27. Smith K. O., Kennell W. L., Poirier R. H., Lynd F. T. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine). Antimicrob Agents Chemother. 1980 Feb;17(2):144–150. doi: 10.1128/aac.17.2.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Trousdale M. D., Nesburn A. B., Willey D. E., Taaid H. Efficacy of BW759 (9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]guanine) against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res. 1984 Aug;3(8):1007–1015. doi: 10.3109/02713688409011747. [DOI] [PubMed] [Google Scholar]
  29. Wilson F. M., 2nd Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979 Sep-Oct;24(2):57–88. doi: 10.1016/0039-6257(79)90125-5. [DOI] [PubMed] [Google Scholar]
  30. Yao G. Q., Grill S., Egan W., Cheng Y. C. Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification. Antimicrob Agents Chemother. 1993 Jul;37(7):1420–1425. doi: 10.1128/aac.37.7.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. la Lau C., Oosterhuis J. A., Versteeg J., van Rij G., Renardel de Lavalette J. G., Craandijk A., Lamers W. P., Lamers W. P. Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial. Br J Ophthalmol. 1982 Aug;66(8):506–508. doi: 10.1136/bjo.66.8.506. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES